1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

28 Feb 2024
Admin
News Article

Takeda Partners with Biological E for Dengue Vaccine

Takeda inks partnership with Biological E for 'Make in India' manufacturing for its dengue vaccine

Overview

Takeda inks strategic partnership with Biological E. Limited, the former’s dengue vaccine, TAK-003. The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030.

Biological E: future production

Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 million doses annually within the decade.

Contribution of Telangana Government

Words from Govt. Leaders

Announcing the partnership at BioAsia 2024, a regional life sciences and healthcare forum organized by the Telangana chief minister , Anumula Revanth Reddy, said, ""We are delighted that Hyderabad in Telangana will host the facility where the dengue vaccine, a result of the partnership between Takeda and Biological E., will be manufactured. The state of Telangana offers a conducive R&D and manufacturing environment with a focus on life sciences, particularly vaccines and biologics, and I am delighted that the dengue vaccine production in Hyderabad is aimed at accelerating its access in India and other endemic countries.""
"Leveraging Takeda's technological expertise and Biological E's manufacturing capabilities will support greater accessibility and affordability of dengue vaccines, contributing to the nation's healthcare resilience and future preparedness. We are happy to support this partnership among science, government and industry to drive and scale innovations?for universal health coverage,""?said Telangana minister of industry & commerce Duddilla Sridhar Babu.

Words from Takeda

“Our long-term goal for our dengue program has been to make TAK-003 broadly available to those at risk who may benefit from immunization. Within the last year, we've successfully launched in private markets, are now launching in some public programmes, and working with partners to support a broader public health impact,"" said Gary Dubin, M.D., president of the Global Vaccine Business Unit, Takeda.

Dengue: Epidemiology

As the fastest-spreading mosquito-borne viral disease, about half of the world's population is now at risk of dengue.
In India and Southeast Asia, 1.3 billion people live in dengue-endemic areas, with Thailand, India, and Indonesia among some of the most highly endemic countries.
The recent recommendations made by WHO's Strategic Advisory Group of Experts (SAGE) on immunization recommended Takeda's dengue vaccine for introduction in settings with high dengue burden and high transmission intensity to maximize public health impact.

Wods from Dion Warren (Takeda leader)

"This strategic partnership reaffirms our commitment to supplying vaccines to protect the health of people around the world and our efforts to strengthen partnerships in Asia. With vaccine approvals in Thailand, Indonesia, and recently in Malaysia, we are excited for a future where integrated protection against dengue can potentially improve the lives of countless people in India, Southeast Asia and beyond"", said Dion Warren, Head of India and Southeast Asia Multi-country Organisation, Takeda.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!